Medicus, Vol. 32 No. 1. Psihoze, 2023.
Review article
Long-Acting Antipsychotics
Boran Uglešić
Tonći Mastelić
Abstract
Long-acting antipsychotics are an important tool in the treatment of schizophrenia, but also of other disorders with psychotic elements. The importance of their early introduction, even in the first psychotic episode, is being emphasized more and more. Long-acting antipsychotics are superior to oral antipsychotics in terms of rehospitalization, frequency and severity of side effects, level of functional recovery and mortality rate. Long-acting haloperidol, fluphenazine, risperidone, paliperidone, olanzapine and aripiprazole are available in the Republic of Croatia. Although they are extremely effective, they are not used enough. It is necessary to inform psychiatrists and health workers on their benefits. Patients can benefit in different ways and reduce the stigma of long-acting antipsychotics as a therapy reserved for harsh clinical pictures. Based on national and global experiences, methods for patients who use long-acting antipsychotics can be improved and their use can be expanded. This ultimately benefits the patients, their families, doctors, and the healthcare system as a whole.
Keywords
long-acting antipsychotics; schizophrenia; stigma; psychoeducation; Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
Hrčak ID:
308622
URI
Publication date:
9.10.2023.
Visits: 734 *